## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%); PEG 1.65 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. The Future of Bone Sonometer Market 2032 Industry Forecast**
- Source: openPR.com | 20251229T072740 | Bullish | Relevance: 100%
- The Bone Sonometer Market is projected to grow from USD 1,336.8 Mn in 2025 to USD 1,996.8 Mn by 2032, exhibiting a CAGR of 5.9%. This growth is driven by rising industry demand, expanding applications, and technological advancements, according to a report by Coherent Market Insights. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscape, with a detailed regional assessment to inform strategic business decisions.

**2. Skin Rejuvenation Devices Market Forecast Report: Strategic Insights, Expansion Opportunities and Key Players to 2032 |Cutera Inc., Hologic, Inc., Lutronic Corporation**
- Source: openPR.com | 20251229T060825 | Somewhat-Bullish | Relevance: 93%
- The global skin rejuvenation devices market is projected to grow from US$2,227.4 million in 2022 to exhibit a CAGR of 9.5% during 2022-2030, driven by rapid innovation and shifting regional dynamics. This report offers strategic insights, segmentation by type, application, and region, and profiles key industry players like Cutera Inc. and Hologic Inc. It also highlights investment hotspots and production/consumption patterns to help stakeholders capitalize on upcoming opportunities.

**3. Why a $7.3 Million Bet on Core Scientific Looked Smart at Quarter-End but Got Tested 30% Later**
- Source: Yahoo Finance | 20251228T163500 | Neutral | Relevance: 65%
- PSquared Asset Management initiated a significant $7.28 million stake in Core Scientific during the third quarter of 2025, betting on its stabilizing digital infrastructure and potential merger with CoreWeave. However, the stock price faced a 30% decline after the merger agreement was terminated due to shareholder disapproval. Despite this setback, Core Scientific still possesses valuable power infrastructure and is shifting its focus towards hosting and AI-adjacent workloads.

**4. Why a $7.3 Million Bet on Core Scientific Looked Smart at Quarter-End but Got Tested 30% Later**
- Source: The Globe and Mail | 20251228T103500 | Neutral | Relevance: 59%
- PSquared Asset Management initiated a significant position in Core Scientific during the third quarter, which initially appeared to be a smart move due to the company's stabilizing digital infrastructure and potential merger. However, Core Scientific's stock price dropped by nearly 30% after the termination of its merger agreement with CoreWeave, raising questions about execution risk. Despite the stock plunge, the underlying operational shift towards hosting and compute services utilizing valuable power infrastructure remains.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($0.00M) |
| Sells | 26 ($6.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.65 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.8x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.6B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.65 |
| Forward P/E | 14.9 |
| Current P/E | 16.3 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.2% (minimal 5-day change). Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). RSI neutral at 50. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.25% (CS: 27) | Neutral |
| RSI_14 | 49.5 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.126x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.51
- **Stop Loss:** $73.91 (0.8% risk)
- **Target:** $75.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2300
- **Position Value:** $171,373.00
- **Portfolio %:** 171.37%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*